Cargando…

A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study

PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wettergren, Yvonne, Taflin, Helena, Odin, Elisabeth, Kodeda, Karl, Derwinger, Kristoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281361/
https://www.ncbi.nlm.nih.gov/pubmed/25342290
http://dx.doi.org/10.1007/s00280-014-2611-9
_version_ 1782350982328352768
author Wettergren, Yvonne
Taflin, Helena
Odin, Elisabeth
Kodeda, Karl
Derwinger, Kristoffer
author_facet Wettergren, Yvonne
Taflin, Helena
Odin, Elisabeth
Kodeda, Karl
Derwinger, Kristoffer
author_sort Wettergren, Yvonne
collection PubMed
description PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, Modufolin(®). The aim was to compare the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin(®) or Isovorin(®) (levo-leucovorin). METHODS: Thirty-two patients scheduled for colon resection were randomized to receive Modufolin(®) or Isovorin(®) at dosage of 60 or 200 mg/m(2). The study drug was given as one i.v. bolus injection after anesthesia. Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery. Tissue biopsies were collected at surgery. Folate metabolites were analyzed by LC-MS/MS. RESULTS: MethyleneTHF and THF concentrations were significantly higher in mucosa (p < 0.01, both dosages) and tumors (p < 0.01, 200 mg/m(2)) after Modufolin(®) as compared to Isovorin(®) administration. The results correlated with PK observations. The Modufolin(®) to Isovorin(®) C (max) ratio for methyleneTHF was 113 at 200 mg/m(2) and 52 at 60 mg/m(2); the AUC(last) ratios were 17 and 9, respectively. The THF plasma concentrations were also higher after Modufolin(®) administration (C (max) ratio 23, AUC(last) ratio 13 at 200 mg/m(2); C (max) ratio 15, AUC(last) ratio 11 at 60 mg/m(2)). CONCLUSION: Modufolin(®) administration resulted in significantly higher methyleneTHF levels than Isovorin(®) and may potentially increase the efficacy of 5-fluorouracil-based chemotherapy. The results encourage further evaluation of Modufolin(®) as a substitute to Isovorin(®) including the potential clinical benefits. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-014-2611-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4281361
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-42813612015-01-05 A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study Wettergren, Yvonne Taflin, Helena Odin, Elisabeth Kodeda, Karl Derwinger, Kristoffer Cancer Chemother Pharmacol Original Article PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, Modufolin(®). The aim was to compare the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin(®) or Isovorin(®) (levo-leucovorin). METHODS: Thirty-two patients scheduled for colon resection were randomized to receive Modufolin(®) or Isovorin(®) at dosage of 60 or 200 mg/m(2). The study drug was given as one i.v. bolus injection after anesthesia. Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery. Tissue biopsies were collected at surgery. Folate metabolites were analyzed by LC-MS/MS. RESULTS: MethyleneTHF and THF concentrations were significantly higher in mucosa (p < 0.01, both dosages) and tumors (p < 0.01, 200 mg/m(2)) after Modufolin(®) as compared to Isovorin(®) administration. The results correlated with PK observations. The Modufolin(®) to Isovorin(®) C (max) ratio for methyleneTHF was 113 at 200 mg/m(2) and 52 at 60 mg/m(2); the AUC(last) ratios were 17 and 9, respectively. The THF plasma concentrations were also higher after Modufolin(®) administration (C (max) ratio 23, AUC(last) ratio 13 at 200 mg/m(2); C (max) ratio 15, AUC(last) ratio 11 at 60 mg/m(2)). CONCLUSION: Modufolin(®) administration resulted in significantly higher methyleneTHF levels than Isovorin(®) and may potentially increase the efficacy of 5-fluorouracil-based chemotherapy. The results encourage further evaluation of Modufolin(®) as a substitute to Isovorin(®) including the potential clinical benefits. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-014-2611-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-10-24 2015 /pmc/articles/PMC4281361/ /pubmed/25342290 http://dx.doi.org/10.1007/s00280-014-2611-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Wettergren, Yvonne
Taflin, Helena
Odin, Elisabeth
Kodeda, Karl
Derwinger, Kristoffer
A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title_full A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title_fullStr A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title_full_unstemmed A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title_short A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
title_sort pharmacokinetic and pharmacodynamic investigation of modufolin(®) compared to isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281361/
https://www.ncbi.nlm.nih.gov/pubmed/25342290
http://dx.doi.org/10.1007/s00280-014-2611-9
work_keys_str_mv AT wettergrenyvonne apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT taflinhelena apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT odinelisabeth apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT kodedakarl apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT derwingerkristoffer apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT wettergrenyvonne pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT taflinhelena pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT odinelisabeth pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT kodedakarl pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy
AT derwingerkristoffer pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy